Kingsley L. Taft

Kingsley L. Taft

PartnerCo-Chair, Life Sciences
he/him/his
Kingsley L. Taft
Boston
+1 617 570 1222

Kingsley Taft is a partner and co-chair of Goodwin's Life Sciences group and a former member of the Allocations Committee. He represents emerging to mature life sciences companies in all aspects of their business and legal affairs, including company formation, venture financings, strategic alliances, M&A, IPOs and other capital market transactions, and other financing and commercial transactions. Kingsley has extensive experience in assisting clients with JVs, strategic alliances, licenses, and collaborations.

Kingsley has been recognized as a leading life sciences attorney by numerous legal guides. He has been annually ranked for more than 15 years in Chambers USA: America’s Leading Lawyers for Business (Nationwide, Life Sciences: Corporate/Commercial — Band 1). Kingsley was inducted into the LMG Life Sciences Hall of Fame, named a Biotechnology and Life Sciences Lawyer of the Year in 2022 by The Best Lawyers in America and named a Life Sciences Thought Leader by Who’s Who Legal - Global Elite.

Before attending Harvard Law School, Kingsley earned a BS in Chemistry from Yale University and a PhD in Chemistry from the Massachusetts Institute of Technology.

Representative Matters

  • Heidelberg Pharma in its royalty financing agreement with Healthcare Royalty (HCRx) for up to $115 million, where HCRx will acquire Heidelberg Pharma’s royalties on sales of Zircaix™ (TLX250-CDx), a microdose radiopharmaceutical Positron Emission Tomography (PET) imaging agent for the diagnosis and follow up of clear cell renal cancer.
  • Isomorphic Labs on its strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets, for an upfront payment of $37.5 million and up to $1.2 billion in performance-based milestone payments.
  • Flagship Pioneering in Novo Nordisk’s separate research collaborations with Omega Therapeutics, Inc. to leverage its proprietary platform technology to develop an epigenomic controller designed to enhance metabolic activity as a part of a potential new treatment approach for obesity management and Cellarity, Inc. to unravel novel biological drivers of metabolic dysfunction-associated steatohepatitis and will leverage Cellarity’s platform to develop a small molecule therapy against this disease.
  • Q32 Bio Inc. in its definitive merger agreement to combine with Homology Medicines, Inc.
  • Mablink Bioscience on its acquisition by Eli Lilly and Company
  • Teva Pharmaceuticals in its collaboration with Sanofi to co-develop and co-commercialize asset TEV ‘574, currently in Phase 2b clinical trials, for the treatment of Ulcerative Colitis and Crohn's Disease, for an upfront payment of $500 million and up to $1 billion in development and launch milestones
  • Aditum Bio and its new portfolio company, Celexor Bio, in an in-licensing transaction with Inmagene Biopharmaceuticals
  • EryDel SpA on its sale to Quince Therapeutics for up to $485 million in potential downstream milestones for the treatment of rare diseases delivered by its proprietary red blood cell technology
  • Flagship Pioneering on its partnership with Pfizer to create a new pipeline of innovative medicines for $100 million combined upfront commitment and up to $700 million in milestones plus royalties for each successfully commercialized program
  • Korro Bio in its definitive merger agreement with Frequency Therapeutics to focus on the advancement of Korro Bio’s portfolio of RNA editing programs 
  • Nanobiotix S.A. in its worldwide licensing agreement with Janssen Pharmaceutica NV for the development and commercialization of NBTXR3, a first-in class radioenhancer developed by Nanobiotix designed to destroy tumors through physical cell death when activated by radiotherapy for an upfront payment of $30 million and up to $1.8 billion upon the achievement of certain development, regulatory, and sales milestones
  • Surface Oncology on its acquisition by Coherus BioSciences for $40 million net cash at closing
  • Haystack Oncology on its acquisition by Quest Diagnostics for $300 million in cash at closing and up to an additional $150 million on achieving future performance milestones
  • Tubulis in its strategic license agreement with Bristol Myers Squibb to develop differentiated antibody-drug conjugates (ADCs) for cancer, for an upfront payment of $22.75 million and up to $1 billion in development, regulatory, and commercial milestones plus royalties
  • Moderna Therapeutics in its strategic collaboration with Generation Bio Co. to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines, for an upfront payment of $40 million and a $36 million equity investment issued at a premium over recent share prices
  • Moderna Therapeutics in its strategic research and development collaboration with Life Edit Therapeutics Inc., an ElevateBio company, to discover and develop in vivo mRNA gene editing therapies; Life Edit will receive an upfront payment and is eligible to receive potential development, regulatory, and commercial milestone payments, in addition to tiered royalties
  • Entrada Therapeutics on its global collaboration with Vertex Pharmaceuticals Incorporated to focus on discovering and developing intracellular Endosomal Escape Vehicle (EEV™) therapeutics for myotonic dystrophy type 1 (DM1), for an upfront payment of $250 million and up to $485 million for the successful achievement of certain research, development, regulatory, and commercial milestones
  • FibroGen, Inc. on its capped royalty monetization financing with NovaQuest Capital Management, for an upfront payment of $50 million in exchange for 22.5% of its future royalties on sales of EVRENZO® (roxadustat) by Astellas in Japan, Europe, and certain other territories
  • SpringWorks Therapeutics in its non-exclusive license and collaboration agreement with GSK for nirogacestat, SpringWorks’ investigational oral gamma secretase inhibitor, in combination with Blenrep, GSK’s antibody-drug conjugate targeting B-cell maturation antigen, for up to $550 million in additional payments
  • Q32 Bio in its collaboration and option agreement with Horizon Therapeutics Ireland DAC to research, develop and commercialize ADX-914 for the treatment of autoimmune diseases, for up to $55 million in near-term payments and $645 million in closing and milestone payments
  • Palleon Pharmaceuticals in its strategic collaboration agreement with Shanghai Henlius Biotech to develop and commercialize two bifunctional sialidase programs from Palleon’s EAGLE (Enzyme-Antibody Glyco-Ligand Editing) immuno-oncology platform
  • HIBio in its equity participation agreement and license agreements with MorphoSys to develop and commercialize MorphoSys’ felzartamab, and MOR210
  • Flagship Pioneering in its strategic collaboration with Novo Nordisk A/S to create a portfolio of novel research programs to develop transformational medicines
  • Ncardia Belgium SA in its strategic collaboration with Quell Therapeutics to develop a pluripotent stem cell (iPSC) -derived T-regulatory (Treg) cell therapy platform
  • Jocasta Neuroscience in its exclusive license agreement with UNITY Biotechnology to continue development of α-klotho program, with an up-front payment and additional payments based on milestones and sales-based royalties, per indication
  • Prime Medicine in its exclusive option and research collaboration agreement with Myeloid Therapeutics, with an upfront of $45 million
  • Arrakis Therapeutics on its research collaboration agreement with Amgen (NASDAQ: AMGN), focused on the discovery and development of RNA degrader therapeutics against a range of difficult-to-drug targets in multiple therapeutic areas, for $75 million upfront and up to several billion dollars in milestones and royalties
  • Acadia Pharmaceuticals on its collaboration agreement with Stoke Therapeutics to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system (CNS), for an upfront payment of $60 million and up to $907 million in milestones and royalties
  • Absci Corporation on its research collaboration agreement with Merck, using Absci’s AI-powered Integrated Drug Creation™ Platform for up to $610 million in upfront fees and milestone payments
  • Generate Biomedicines on its research collaboration agreement with Amgen to discover and create protein therapeutics for five clinical targets across several therapeutic areas and multiple modalities, for an upfront payment of $50 million for the initial five programs with a potential transaction value of $1.9 billion plus future royalties 
  • Blueprint Medicines on its acquisition of Lengo Therapeutics for $250 million upfront and up to $465 million in total for an oral precision therapy in development for the treatment of non-small cell lung cancer (NSCLC)
  • Moderna Therapeutics in its strategic research and development collaboration with Metagenomi focused on advancing new gene editing systems for in vivo human therapeutic applications
  • Flagship Pioneering in a first-of-its-kind strategic partnership with the Cystic Fibrosis Foundation and Pioneering Medicines to develop therapeutics that address the unmet needs of people living with cystic fibrosis, with $110 million committed funding
  • Codiak BioSciences in the sale of its exosome manufacturing facility located in Lexington, Massachusetts (US) to Lonza; Codiak will receive approximately $65 million of cGMP manufacturing services in kind, and Lonza will gain worldwide access and sub-licensable rights to Codiak's high-throughput perfusion-based cGMP process for exosome manufacturing
  • Exicure in its exclusive collaboration agreement with Ipsen (Euronext: IPN; ADR: IPSEY) to research, develop, and commercialize novel Spherical Nucleic Acids (SNAs) as potential investigational treatments for Huntington’s disease and Angelman syndrome, for an upfront payment of $20 million and up to $1 billion in milestone payments
  • Arvinas on its global collaboration with Pfizer (NYSE: PFE) to develop and commercialize ARV-471, an investigational oral PROTAC® (PROteolysis TArgeting Chimera) estrogen receptor protein degrader, for an upfront payment of $650 million and up to $400 million in approval milestones and up to $1 billion in commercial milestones
  • Amathus Therapeutics on its strategic collaboration with Merck to develop novel small molecule therapeutic candidates for neurodegenerative diseases, for an upfront payment and milestone payments associated with the successful development candidates in excess of $500 million per program
  • AbSci on its acquisition of deep learning company, Denovium, Inc.
  • Biond Biologics Ltd. on its exclusive worldwide license agreement with Sanofi, for the development and commercialization of BND-22, for an upfront payment of $125 million and up to more than $1 billion in development, regulatory, and sales milestones, as well as tiered double digit royalty payments
  • Celsius Therapeutics on its strategic collaboration with Servier, focused on the identification and validation of novel colorectal cancer (CRC) drug targets, for an upfront payment and research funding and up to $700 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales
  • Surface Oncology on its exclusive agreement with GSK for Surface Oncology’s preclinical program SRF813, for an upfront payment of $85 million and up to $730 million in future milestone payments, as well as be eligible to receive tiered royalties on global net sales
  • Cadent Therapeutics on its acquisition by Novartis for an upfront payment of $210 million and up to $560 million in milestone payments, for an overall deal value of up to $770 million, for its neuroscience portfolio
  • Relay Therapeutics on its collaboration with Genentech, a member of the Roche Group, for the development and commercialization of RLY-1971, with an upfront payment of $75 million, a near-term milestone of $25 million and up to $695 million in additional potential milestones, plus royalties on product sales
  • insitro on its collaboration with Bristol Myers Squibb for novel therapies to treat amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), with an upfront payment of $50 million, a near-term milestone of $20 million, royalties and up to an aggregate $2 billion in milestones
  • Vedere Bio on its acquisition by Novartis for $150 million upfront and up to $130 million in milestone payments, for an overall deal value of up to $280 million, for its novel optogenetics AAV gene therapy
  • SpringWorks Therapeutics on its exclusive arrangement with Jazz Pharmaceuticals for SpringWorks’ fatty acid amide hydrolase inhibitor program, for an upfront payment of $35 million, up to $375 million in milestones and royalties in the mid- to high-single digit percentages
  • Thrive Earlier Detection Corp. on its acquisition by Exact Sciences Corp. for cash and stock of $1.7 billion at closing and up to $450 million in milestones, for an overall deal value of up to $2.15 billion
  • HiFiBiO on its collaboration with Kite, a Gilead company, in acute myeloid leukemia
  • Teva Pharmaceuticals on its collaboration with Alvotech for the commercialization in the U.S. of five biosimilar product candidates, for an upfront payment, milestones and profit share
  • Blueprint Medicines on its global collaboration with F. Hoffmann-La Roche and Genentech for pralsetinib to treat cancer driven by oncogenic RET alterations, for an upfront of $675 million, equity investment of $100 million, up to $927 million in milestones, and a 50/50 US profit share and ex-US royalties
  • RTW Investments and Ji Xing Pharmaceuticals on a strategic licensing and financing collaboration with Cytokinetics, for committed capital, funding and sale proceeds of up to $250 million from and up to $200 million in milestone payments plus royalties on future sales in certain Asian countries
  • Corvidia Therapeutics in its acquisition by Novo Nordisk for $725 million up-front and up to $2.1 billion in total for transformative cardio-renal therapies
  • Alnylam Pharmaceuticals in its four strategic financing transactions with Blackstone for the advancement of innovative RNA interference (RNAi) medicines that have the potential to transform the lives of patients suffering from a range of debilitating diseases, valued at $2 billion
  • Arrakis Therapeutics in its strategic collaboration with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas, for $190 million up-front and up to more than several billion dollars
  • Flexion Therapeutics in its exclusive license agreement with HK Tainuo and Jiangsu Tainuo (a subsidiary of China Shijiazhuang Pharmaceutical) for the development and commercialization of ZILRETTA in Greater China for an upfront payment of $10 million and up to more than $30 million in milestone payments
  • Promedior Inc. in its acquisition by Roche for $390 million up-front and up to $1.4 billion in total value, for its lead asset PRM-151 for treatment of idiopathic pulmonary fibrosis (IPF)
  • Semma Therapeutics in its acquisition by Vertex Pharmaceuticals for $950 million up-front, for its stem cell-derived human islets technology as a potentially curative treatment for type 1 diabetes
  • Ultragenyx in its partnership with GeneTx to advance treatment for Angelman Syndrome for $20 million up-front in return for an option to acquire the company
  • insitro in its strategic collaboration with Gilead Sciences to develop therapies for patients with nonalcoholic steatohepatitis (NASH), with up to $50 million in near-term payments and $1 billion in deal value
  • Alnylam Pharmaceuticals in its collaboration with Regeneron for new RNA interference (RNAi) therapeutics focused on ocular and central nervous system (CNS) diseases with announced deal value up to $1 billion, in $800 million through upfront cash and equity investment and $200 million in near-term milestones
  • Ipsen in its acquisition of Clementia Pharmaceuticals with a transaction value of $1.31 billion, including a CVR based on the multiple osteochondromas indication for palovarotene
  • Verseau Therapeutics on its partnership agreement with 3SBio Inc. focused on novel monoclonal antibodies in the field of immuno-oncology for a broad range of cancers, along with a $10 million Series B investment
  • Esperion Therapeutics in its agreement with Daiichi Sankyo Europe regarding bempedoic acid and combinations in Europe, for $300 million upfront, up to $900 million in total milestones, and royalties
  • Scholar Rock in its collaboration with Gilead Sciences for inhibitors of transforming growth factor beta (TGFβ) activation to treat fibrotic diseases, for $80 million up front and up to $1.4 billion in milestones
  • MacroGenics in its arrangement with Zai Lab for Margetuximab, MGD013 and a TRIDENT™ molecule in greater China, for $25 million upfront, up to $140 million in milestone payments, and double-digit royalties
  • SpringWorks Therapeutics in its global clinical collaboration with BeiGene to evaluate combining BeiGene’s investigational RAF dimer inhibitor and SpringWorks Therapeutics’ investigational MEK inhibitor
  • Ambys Medicines in forming a strategic partnership with Takeda and concurrent $140 million funding
  • Wave Life Sciences in its strategic collaboration with Takeda to develop nucleic acid therapies for disorders of the central nervous system for $110 million upfront and up to $2 billion in milestone payments
  • Aerpio Therapeutics in its global license agreement with Gossamer Bio, with $20 million up-front, potential milestones of up to $400 million, and royalties ranging from a high single digit to mid-teen percentage
  • Foundation Medicine in its collaboration agreement and equity transaction with Roche, with total deal value in excess of $1 billion and subsequent merger with Roche valued at $2.4 billion
  • Moderna Therapeutics in numerous strategic transactions with AstraZeneca, Merck and others with upfront deal value in excess of $1 billion in cash and equity, plus downstream payments
  • Fresenius Medical Care in global partnership with Humacyte to commercialize the investigational human acellular vessel HUMACYL; Fresenius made a $150 million equity investment in Humacyte
  • Warp Drive Bio in its collaboration with Roche on novel classes of antibiotics, valued up to $387 million
  • Dimension Therapeutics in its $151 tender offer and contested sale to Ultragenyx
  • Teva Pharmaceuticals in three related sales of its specialty global women’s health business for a combined deal value of $2.5 billion, CooperSurgical, CVC Capital Partners and Foundation Consumer Healthcare
  • Delinia Therapeutics in its sale to Celgene, valued up to $775 million with up-front payment of $300 million
  • Pieris Pharmaceuticals in its strategic collaboration with AstraZeneca to develop novel inhaled drugs that leverage Pieris’ Anticalin platform, for deal value of up to $2.1 billion
  • Medicxi Ventures as an investor in Impact Biomedicines in its sale to Celgene for up to $7 billion
  • Royalty Pharma in its acquisition from Perrigo Company of royalty rights to Tysabri for up to $2.8 billion
  • Teva Pharmaceuticals in its global agreement with Regeneron for the phase 3 novel nerve growth factor antibody fasinumab, for $250 million upfront and a share in its global commercial value
  • Pieris Pharmaceuticals in its collaboration with Servier for a dual-checkpoint inhibitor and up to seven other immuno-oncology bispecific drug candidates, for a deal value of up to €1.7 billion
  • Morgan Stanley as financial advisor to Stemcentrx in its sale to AbbVie for $5.8 billion in cash and stock, and up to an additional $4 billion in cash in success-based milestone payments
  • Intellia Therapeutics in its multi-year collaboration with Regeneron on CRISPR/Cas gene-editing technology for in vivo therapeutic development, with $75 million upfront and potential milestone and royalty payments
  • Padlock Therapeutics in its sale to Bristol-Myers Squibb, valued up to $600 million with up-front and near-term payments of $225 million
  • Blueprint Medicines in its collaboration with Roche, up to $1 billion in value with $45 million upfront
  • Surface Oncology in its collaboration with Novartis to develop next generation immunotherapeutics, with Surface to receive up to $170 million in near term cash, plus milestones and royalties
  • Promedior in its option agreement with Bristol-Myers Squibb with potential deal value of up to $1.25 billion
  • Unum Therapeutics in its strategic collaboration with Seattle Genetics to develop and commercialize novel antibody-coupled T-cell receptor (ACTR) therapies for cancer, with potential deal value of $615 million
  • Teva Pharmaceuticals in its acquisition of Labrys Biologics, for $200 million cash and up to $825 million
  • Nogra Pharma in its $710 million global license agreement with Celgene for therapies to treat Crohn’s disease with a total potential deal value up to $2.6 billion in milestones, plus royalties
  • bluebird bio in its global collaboration with Celgene and subsequent update for gene therapies to treat cancer with deal value up to $300 million

  • Prime Medicine in its $199 million initial public offering
  • Scholar Rock in its $205 million registered direct offering and $92.5 million underwritten offering of common stock
  • Vigil Neuroscience in its $98 million initial public offering
  • Absci Corporation in its $230 million initial public offering and $86.4 million follow-on offering
  • SpringWorks Therapeutics in its $186.3 million initial public offering, $287.5 million and $316.25 million follow-on offerings and $225 million private placement
  • Kaleido Biosciences in its $75 million initial public offering and its $35.6 million follow-on offering
  • Scholar Rock in its $86 million initial public offering, and subsequent $51 million and $230 million follow-on offerings
  • Axcella Health in its $71 million initial public offering and $25 million and $34 million registered direct offering
  • HOOKIPA Pharma in its $84 million initial public offering
  • Moderna Therapeutics in its $604 million initial public offering and follow-on offerings
  • Blueprint Medicines in its $147 million initial public offering and subsequent $143 million, $230 million, $350 million, and $327 million follow-on offerings
  • Aerpio Therapeutics in its $40 million reverse merger and private placement and subsequent $45 million follow-on offering and up-listing to NASDAQ
  • Surface Oncology in its $108 million initial public offering and concurrent $11.5 million private placement
  • Unum Therapeutics in its $69 million initial public offering and concurrent $5 million private placement
  • aTyr Pharma in its $75 million initial public offering and $45 million subsequent equity financing
  • Fate Therapeutics in its $40 million IPO, $30 million follow-on offering, and $57 million structured PIPE
  • Ra Pharmaceuticals in its $105 million initial public offering
  • Dimension Therapeutics in its $72 million initial public offering
  • Foundation Medicine in its $106 million initial public offering

  • Human Immunology Biosciences (HI-Bio) in its $95 million Series B financing to advance clinical development of felzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies.
  • Mariana Oncology Inc. on its oversubscribed $175 million Series B financing to support the advancement of Mariana Oncology’s novel portfolio of precision, next-generation radiopharmaceuticals including its lead candidate, MC-339, as the company transitions into a clinical-stage organization
  • K36 Therapeutics on its $70 million Series B financing to support the ongoing Phase 1 study of KTX-1001, planned clinical studies of KTX-1001 in combination with existing standard-of-care agents in multiple myeloma, and the expansion of KTX-1001 into additional hematological and solid tumor indications
  • AAVantgarde Bio on its €61 million Series A financing to advance two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery into the clinic
  • Rapport Therapeutics on its launch and $100 million Series A financing to identify receptor-associated proteins that enable the identification of precision targeted small molecule drugs that have the potential to transform the treatment of neurological disorders
  • Bicara Therapeutics on its oversubscribed $108 million Series B financing to advance the company’s lead program BCA101 and its pipeline of investigational candidates to treat solid tumor cancers
  • FogPharma in its $178 million Series D and $145 million Series E financings to accelerate FogPharma’s growing pipeline of hyperstabilized α-helical (Helicon™) polypeptide therapeutics
  • Webster Equity Partners in three concurrent transactions, including the purchase of a 50% interest in Corium Pharma Solutions, Inc., a substantial minority investment in Corium Therapeutics Holdings, LLC and a substantial minority investment in the parent company of Radius Health, Inc.
  • Sonothera in its $60 million Series A financing and the launch of the company for ultrasound-guided, nonviral, gene therapy platform and treatments
  • Nuvig Therapeutics in its $47 million Series A financing and the launch of the company to develop novel therapeutics that induce mechanisms of immune homeostasis and treat autoimmune diseases without compromising normal immune function.
  • MOMA Therapeutics on its $150 million Series B Financing to further develop product opportunities and advance a rich pipeline of precision oncology programs.
  • LifeMine Therapeutics on its $175 million Series C financing to further advance LifeMine’s reinvention of drug discovery by mining genetically-encoded small molecules (GEMs) from the biosphere
  • Curie Therapeutics on its $75 million Series A financing to further its mission of transforming cancer care with precision radiopharmaceuticals
  • Delix Therapeutics on its $70 Million Series A financing to advance pipeline of novel psychoplastogen therapeutics to treat brain disorders
  • Korro Bio on its $116 million Series B financing to enable Korro to advance its lead program in development for patients with Alpha-1 Antitrypsin Deficiency (AATD)
  • Vigil Neuroscience on its $90 million Series B financing to further advance Vigil’s proprietary pipeline of microglia-targeted medicines for the treatment of neurodegeneration
  • InterVenn Biosciences on its $201 million Series C and $34 million Series B fundraising to accelerate development and commercialization of Dawn™, the company’s liquid biopsy assay for immune checkpoint inhibitor response prediction, and to expand the network of partners on the company’s AI-driven glycoproteomics platform
  • Prime Medicine™ on its launch and funding rounds totaling $315 million to develop a versatile gene editing technology that can truly "search and replace" to restore normal genetic function and address the fundamental causes of disease
  • Vedere Bio II on its launch and $77 million Series A financing to develop the next generation of ocular gene therapies
  • AbSci on its $125 million crossover financing and its $65 million Series E equity financing to increase production capacity, accelerate facility expansion and support research and development activities
  • Palleon Pharmaceuticals in its $100 million Series B to develop drugs targeting glycan-mediated immune regulation to treat cancer and inflammatory diseases
  • Q32 Bio on its $60 million Series B financing to propel the company’s groundbreaking tissue-targeted complement regulation platform
  • Hillhouse Capital on its investment in Everest Medicines as a co-lead investor in Everest Medicine’s Series C financing of $310 million
  • Cerevance on its $45 million Series B financing to identify novel therapeutic targets for central nervous system diseases
  • Moma Therapeutics on its launch and $86 million Series A financing to establish a platform focused on the drug discovery of molecular machines
  • Xilio Therapeutics on its $100.5 million Series B financing to progress Xilio’s first two therapeutic candidates, XTX201 (tumor-selective IL-2) and XTX101 (tumor-selective aCTLA4 mAb)
  • EQRx in its $200 million Series A financing to create novel, patent-protected medicines at prices that are more affordable for people and sustainable for healthcare systems
  • Triplet Therapeutics, Inc. in its $49 million Series A financing to further its development of transformative treatments for Triplet repeat disorders
  • Verseau Therapeutics in its launch and $50 million financing to create a new class of therapeutics, macrophage checkpoint modulators to benefit patients with cancer, immune and inflammatory diseases
  • Arrakis Therapeutics in its $75 million Series B financing to advance a new class of small-molecule medicines targeting RNA
  • SpringWorks Therapeutics in its $125 million Series B financing to advance two late-stage rare disease oncology programs toward potential regulatory approval
  • Medicxi Ventures in its $40 million Series D financing of Aura Biosciences for ocular melanoma treatments
  • HOOKIPA Pharma in its $37.4 Series D financing to advance its clinical programs
  • Cadent Therapeutics in its $40 million financing round to advance its pipeline of novel therapies for movement and cognitive disorders
  • Akrevia in its $30 million financing to develop highly-potent, targeted immuno-oncology therapeutics
  • Rheostat Therapeutics in its $23 million financing to develop treatments for neurodegenerative disease
  • Alector Corporation in its most recent $133 million financing and prior $29.5 million financing to advance a broad portfolio of IO programs
  • Kaleido Biosciences in its most recent $101 million financing and prior $85 million financing to develop novel chemistries for the human microbiome
  • Corvidia Therapeutics in its most recent $60 million financing and prior $26 million financing and in-license of a clinical stage asset from AstraZeneca to advance its lead clinical programs in chronic kidney disease
  • Quentis Therapeutics in its $48 million financing for cancer immunotherapies
  • Moderna Therapeutics in its most recent $500 million and prior $474 million and $450 equity financings to pioneer mRNA therapeutics
  • Semma Therapeutics in its most recent $114 million financing and prior $44 million financing for stem cell therapies for Type 1 diabetes
  • Arrakis Therapeutics in its $38 million financing to discover a new class of medicines directly targeting RNA
  • Cerevance in its $40 million plus funding and spin-out from Takeda Pharmaceutical for neuroscience
  • Axcella Health in its approximately $80 million financing for amino acid-based products
  • Medicxi Ventures in its approximately $22 million financing of Impact Biomedicines to develop treatments for myeloproliferative neoplasms and other cancers
  • SetPoint Medical in its $100 plus million in financings for its implantable neuromodulation devices
  • Scholar Rock in its $47 million financing and earlier preferred stock financings for therapeutics that target specific growth factors
  • Unum Therapeutics in its $65 million financing for its anti-body directed cellular immunotherapies
  • Surface Oncology in its $35 million financing for cancer immunotherapies
  • Aerpio Therapeutics in its $60 million financings for vascular disease therapies

Credentials

Education

JD1997

Harvard Law School

(magna cum laude)

PhDChemistry1993

Massachusetts Institute of Technology

BSChemistry1989

Yale University

(magna cum laude)

Clerkships

U.S. Court of Appeals for the Federal Circuit, Honorable Raymond C. Clevenger

Admissions

Bars

  • Massachusetts

Recognition & Awards

Kingsley has been recognized by The Best Lawyers in America Best Lawyers for his work in Biotechnology and Life Sciences Practice and Corporate Law 2022-2023.

Kingsley has been recognized by numerous legal guides for legal and life sciences industry expertise. In addition to the three listings noted above, Kingsley has also been named as a leading business lawyer by Chambers USA (Life Sciences: Corporate/Commercial), Chambers Global, U.S. News-Best Lawyers (Biotechnology Law), Chambers Global (Life Sciences:Corporate/Commercial), IFLR1000 (Pharmaceutical sector), LMG Life Sciences (Life Sciences Star), The Legal 500 United States (Healthcare: Life Sciences and Venture Capital and Emerging Companies), PLC Cross-border Life Sciences Handbook (Commercial and Partnering), named to the IAM Global Leaders Guide (2020), IAM Patent 1000 (Licensing), and The International Who’s Who of Life Sciences Lawyers (Transactional).

Under his leadership, Goodwin’s Life Sciences Practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for six out of seven years running (2013 through 2015, and 2017 through 2020), Law360 Life Sciences Group of the Year (2016), LMG Life Sciences’ Corporate Law Firm of the Year (2019) and Venture Capital Law Firm of the Year (2016), and perennial nationwide recognition by Chambers USA.

Publications

While attending law school, he first served as an editor and executive editor of the Harvard Law Review.